<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>330</serviceExecutionTime><Drug id="3809"><DrugName>panadiplon</DrugName><DrugNamesKey><Name id="42755835">panadiplon</Name></DrugNamesKey><DrugSynonyms><Name><Value>FG-10571</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>panadiplon</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>U-78875</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>FD-10571</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NNC-14-0571</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>124423-84-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18995">Pharmacia &amp; Upjohn Co</CompanyOriginator><CompaniesSecondary><Company id="18614">Novo Nordisk A/S</Company><Company id="18995">Pharmacia &amp; Upjohn Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3809" type="Drug"><TargetEntity id="152619" type="siDrug">Panadiplon</TargetEntity></SourceEntity><SourceEntity id="18614" type="Company"><TargetEntity id="4295865996" type="organizationId">Novo Nordisk A/S</TargetEntity></SourceEntity><SourceEntity id="18995" type="Company"><TargetEntity id="4295911110" type="organizationId">Pharmacia &amp; Upjohn Company Inc</TargetEntity></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"></TargetEntity><TargetEntity id="D001008" type="MeSH"></TargetEntity><TargetEntity id="-1384065283" type="omicsDisease"></TargetEntity><TargetEntity id="30" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="173" type="Action"><TargetEntity id="961" type="Mechanism">GABAergic Transmission Enhancers</TargetEntity></SourceEntity><SourceEntity id="81" type="Action"><TargetEntity id="191" type="Mechanism">GABA(A) BZ Site Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="25">Anxiety disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="173">GABA receptor agonist</Action><Action id="81">Benzodiazepine receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2942">Anxiolytic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-01T06:12:02.000Z</LastModificationDate><ChangeDateLast>2005-03-31T17:45:46.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="3809" linkType="Drug"&gt;Panadiplon&lt;/ulink&gt; is a 'benzodiazepine-like' anxiolytic which had been in phase I trials in healthy human volunteers. These trials, however, were discontinued due to early signs of hepatotoxicity [&lt;ulink linkID="205314" linkType="reference"&gt;205314&lt;/ulink&gt;]. The drug resulted from a collaborative agreement between &lt;ulink linkID="18614" linkType="Company"&gt;Novo Nordisk&lt;/ulink&gt; and Upjohn.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Senior Neuroscientist, Pharmaceutical Company&lt;/subtitle&gt;31 July 1997&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; (U-78875) is a non-benzodiazepine anxiolytic agent, which has been dropped from clinical trials during phase I due to evidence of hepatotoxicity, later confirmed in subsequent animal studies [&lt;ulink linkType="reference" linkID="205314"&gt;205314&lt;/ulink&gt;]. The drug was developed for the treatment of anxiety disorders as a result of its promising and unique activity at the benzodiazepine-GABAA receptor complex. While &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; has been shown to have anxiolytic activity [&lt;ulink linkType="reference" linkID="257652"&gt;257652&lt;/ulink&gt;] and generalized to the benzodiazepine, diazepam, in a drug-discrimination paradigm [&lt;ulink linkType="reference" linkID="11953"&gt;11953&lt;/ulink&gt;], it also potently antagonizes diazepam in a variety of other tests [&lt;ulink linkType="reference" linkID="23287"&gt;23287&lt;/ulink&gt;]. This dual agonist/antagonist profile indicates that &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; is a potent, partial agonist, with a low, but demonstrable, intrinsic activity and suggests its utility as an anxiolytic, with a potentially better side-effect profile than the benzodiazepines.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Structure and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; is an imidazo(1,5-a)quinoxaline derivative (imidazo(1,5-a)quinoxalin-4(5H)-one,3-(-5-cyclopropyl-1,2,3-oxadiazol-3-yl)-5-(1-methylethyl)). Imidazo(1,5-a) quinoxalines generally bind with high affinity to the benzodiazepine/GABAA receptor site [&lt;ulink linkType="reference" linkID="160636"&gt;160636&lt;/ulink&gt;]. The antagonistic/partial agonistic properties of &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; probably result, in part, from the relatively planar position of the carbonyl group relative to the ring system, while tetracyclic derivatives of &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt;, with bulky out-of-plane substituents provide full agonists [&lt;ulink linkType="reference" linkID="226735"&gt;226735&lt;/ulink&gt;]. Substitutions in &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; at C6 (H to Cl, CF3, and OCH3) and N5 (isopropyl to methyl, ethyl, and t-butyl) produce little effect on benzodiazepine receptor affinity, altering displacement of 3H-flunitrazepam binding by a maximum of 5 nM to the Ki value [&lt;ulink linkType="reference" linkID="10838"&gt;10838&lt;/ulink&gt;]. The synthesis of labeled &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; (5'-14C and 3A 4-13C) is described in the literature [&lt;ulink linkType="reference" linkID="160641"&gt;160641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In vitro studies of the mechanism of action of &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; have revealed that it binds with high affinity to the benzodiazepine binding site with a Ki of approximately 1.5 nM [&lt;ulink linkType="reference" linkID="23289"&gt;23289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; is anxiolytic in rats in both the Vogel punished licking test, increasing licks accompanied by shock (0.5 mA, 0.1 s) at doses ranging from 1 mg/kg to 10 mg/kg ip, and in the Cook-Davidson conflict procedure [&lt;ulink linkType="reference" linkID="23287"&gt;23287&lt;/ulink&gt;]. In the latter test, in which rats are trained to avoid punished responding, &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; displays a similar potency to diazepam, increasing punished responding at 0.3 and 1 mg/kg ip. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; demonstrates paradoxical antagonistic effects on benzodiazepine-mediated responses, in addition to its anxiolytic effects. Thus in contrast to the Vogel and Cook-Davidson tests, &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; enhances conditioned avoidance in rats at 3 and 10 mg/kg ip, and antagonizes diazepam-induced suppression of avoidance more potently than the benzodiazepine antagonist, flumazenil [&lt;ulink linkType="reference" linkID="23287"&gt;23287&lt;/ulink&gt;]. This antagonist profile is also observed in the rat rotarod performance test, in which 1 and 3 mg/kg of the drug reverses the performance impairment produced by 10 mg/kg diazepam. &lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; also potently inhibits the hypothermia produced by benzodiazepines, including flurazepam, &lt;ulink linkType="Drug" linkID="4723"&gt;zolpidem&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="26708"&gt;Synthelabo&lt;/ulink&gt;) and &lt;ulink linkType="Drug" linkID="2411"&gt;abecarnil&lt;/ulink&gt; (Schering), in mice. This benzodiazepine antagonism is demonstrably more potent than that observed with flumazenil [&lt;ulink linkType="reference" linkID="160642"&gt;160642&lt;/ulink&gt;]. However, in the presence of phenobarbitone, &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; augments the hypothermia, again demonstrating appreciable intrinsic activity. &lt;/para&gt;&lt;para&gt;Other reports have provided evidence that the antagonistic profile of &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; is dependent on both the test and the benzodiazepine receptor state. &lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; generalizes to diazepam in a drug-discrimination procedure, when using low-dose diazepam (1 mg/kg), while high-dose diazepam discrimination (10 mg/kg) is antagonized by the same &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; dose [&lt;ulink linkType="reference" linkID="11953"&gt;11953&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;In a study investigating the viability of assessing serum levels of &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt;, in dogs, by liquid chromatography, oral administration (30 mg/kg) results in a Cmax of 15 microg/ml, with a 15 min serum halflife [&lt;ulink linkType="reference" linkID="10837"&gt;10837&lt;/ulink&gt;]. A single oral dose of 14C-&lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt;, given to female rats, result in the detection in the feces of the parent drug, as a minor component, a major metabolite, an oxidized analog, and an unknown minor metabolite [&lt;ulink linkType="reference" linkID="160637"&gt;160637&lt;/ulink&gt;]. Use of the parent-neutral loss scan screening method, in monkeys given &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt;, has revealed that the drug undergoes N-dealkylation, aryl hydroxylation and conjugation of aryl hydroxides [&lt;ulink linkType="reference" linkID="115868"&gt;115868&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; was discontinued from clinical development because of signs of liver toxicity. Several animal studies have confirmed these findings. Female rabbits given vehicle or &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; (10 or 20 mg/kg, po, once a day) for 14 days. Rabbits given the higher dose of the anxiolytic lose weight and become weak. Dose- and time-related increases in serum transaminase and triglyceride (123%), hepatic lesions, centrilobular necrosis, microvesicular steatosis and a reduction in hepatic glycogen all indicate hepatotoxicity [&lt;ulink linkType="reference" linkID="205314"&gt;205314&lt;/ulink&gt;]. These effects resemble Reye's syndrome and may indicate that &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; inhibits mitochondrial fatty acid oxidation. In vitro experiments, using cultured rabbit hepatocytes, under normoxic conditions have shown that &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt; reduces, cellular ATP and glycogen, without increasing lactate dehydrogenase, suggesting that it inhibits metabolism without directly inducing cell death [&lt;ulink linkType="reference" linkID="247523"&gt;247523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; has been dropped from phase I clinical trials on the basis of hepatotoxicity [&lt;ulink linkType="reference" linkID="205314"&gt;205314&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Studies have not been conducted and are not planned.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Studies have not been conducted and are not planned.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;No side-effects other than the hepatotoxicity have been reported. The lack of extensive clinical trials with the compound precluded investigation into contraindications and further side-effect profiling.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; has been withdrawn from clinical development and, therefore, has no future as a therapeutic agent. &lt;ulink linkType="Drug" linkID="3809"&gt;Panadiplon&lt;/ulink&gt; derivatives, which show a similar profile of activity at the GABAA/benzodiazepine receptor (ie a partial agonist with low intrinsic activity), but which avoid the unwanted hepatotoxicity demonstrated by &lt;ulink linkType="Drug" linkID="3809"&gt;panadiplon&lt;/ulink&gt;, might ultimately be useful therapeutic agents for the treatment of affective disorders. Such a compound might confer the required anxiolytic effects without resulting in the subsequent side-effect problems for which the benzodiazepines are well known, such as dependence liability and sedative effects.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="25">Anxiety disorder</Indication><StatusDate>1996-04-18T00:00:00.000Z</StatusDate><Source id="205314" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18995">Pharmacia &amp; Upjohn Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><Source id="205314" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00190"><Name>Benzodiazepine receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00782"><Name>GABA receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(C)n1c2ccccc2n3cnc(c3c1=O)c4nc(on4)C5CC5</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>